GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Cyclically Adjusted Book per Share

Biogen (BUE:BIIB) Cyclically Adjusted Book per Share : ARS6,605.73 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Biogen Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biogen's adjusted book value per share for the three months ended in Mar. 2024 was ARS88,514.867. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ARS6,605.73 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biogen's average Cyclically Adjusted Book Growth Rate was 9.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 13.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 13.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Biogen was 61.50% per year. The lowest was 3.70% per year. And the median was 13.50% per year.

As of today (2024-04-27), Biogen's current stock price is ARS17470.00. Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ARS6,605.73. Biogen's Cyclically Adjusted PB Ratio of today is 2.64.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 16.44. The lowest was 2.45. And the median was 7.46.


Biogen Cyclically Adjusted Book per Share Historical Data

The historical data trend for Biogen's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted Book per Share Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 579.11 947.50 1,808.36 5,777.02

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,258.78 2,897.65 4,880.56 5,777.02 6,605.73

Competitive Comparison of Biogen's Cyclically Adjusted Book per Share

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PB Ratio falls into.



Biogen Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=88514.867/129.4194*129.4194
=88,514.867

Current CPI (Mar. 2024) = 129.4194.

Biogen Quarterly Data

Book Value per Share CPI Adj_Book
201406 328.974 100.560 423.387
201409 371.751 100.428 479.068
201412 394.042 99.070 514.756
201503 437.433 99.621 568.276
201506 485.781 100.684 624.424
201509 445.970 100.392 574.921
201512 554.950 99.792 719.707
201603 688.482 100.470 886.857
201606 727.553 101.688 925.964
201609 830.769 101.861 1,055.533
201612 890.977 101.863 1,132.011
201703 826.971 102.862 1,040.480
201706 903.443 103.349 1,131.341
201709 1,065.652 104.136 1,324.389
201712 1,138.730 104.011 1,416.904
201803 1,341.978 105.290 1,649.528
201806 1,517.982 106.317 1,847.839
201809 2,514.342 106.507 3,055.250
201812 2,493.195 105.998 3,044.096
201903 2,769.522 107.251 3,341.988
201906 3,131.616 108.070 3,750.289
201909 4,303.104 108.329 5,140.849
201912 4,578.479 108.420 5,465.260
202003 4,654.975 108.902 5,532.009
202006 4,890.673 108.767 5,819.285
202009 5,189.805 109.815 6,116.305
202012 5,713.848 109.897 6,728.884
202103 6,389.459 111.754 7,399.440
202106 6,831.170 114.631 7,712.424
202109 6,942.380 115.734 7,763.288
202112 7,485.763 117.630 8,236.054
202203 8,183.789 121.301 8,731.511
202206 9,838.967 125.017 10,185.457
202209 12,327.470 125.227 12,740.225
202212 15,598.319 125.222 16,121.195
202303 18,822.641 127.348 19,128.834
202306 23,978.287 128.729 24,106.944
202309 34,980.027 129.860 34,861.478
202312 36,870.831 129.419 36,870.831
202403 88,514.867 129.419 88,514.867

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Biogen  (BUE:BIIB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biogen's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=17470.00/6605.73
=2.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 16.44. The lowest was 2.45. And the median was 7.46.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biogen Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BUE:BIIB) Headlines

From GuruFocus

Q1 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at SVB Leerink CNS Forum (Virtual) Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024